These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Increased CD4+CD25+Foxp3+ regulatory T cells in tolerance induced by portal venous injection. He F; Chen Z; Xu S; Cai M; Wu M; Li H; Chen X Surgery; 2009 Jun; 145(6):663-74. PubMed ID: 19486771 [TBL] [Abstract][Full Text] [Related]
3. Comparative analysis of regulatory and effector T cells in progressively growing versus rejecting tumors of similar origins. Bui JD; Uppaluri R; Hsieh CS; Schreiber RD Cancer Res; 2006 Jul; 66(14):7301-9. PubMed ID: 16849580 [TBL] [Abstract][Full Text] [Related]
4. Distinct responses of two hepatocellular carcinoma cell lines of a similar origin to immunotherapies targeting regulatory or effector T cells. Nagayama Y; Hase W; Motoyoshi Y; Saitoh O; Sogawa R; Nakao K Oncol Rep; 2007 May; 17(5):1269-73. PubMed ID: 17390075 [TBL] [Abstract][Full Text] [Related]
5. Two distinct mechanisms of augmented antitumor activity by modulation of immunostimulatory/inhibitory signals. Mitsui J; Nishikawa H; Muraoka D; Wang L; Noguchi T; Sato E; Kondo S; Allison JP; Sakaguchi S; Old LJ; Kato T; Shiku H Clin Cancer Res; 2010 May; 16(10):2781-91. PubMed ID: 20460483 [TBL] [Abstract][Full Text] [Related]
7. Neutralization of interleukin-2 retards the growth of mouse renal cancer. Fukuhara H; Matsumoto A; Kitamura T; Takeuchi T BJU Int; 2006 Jun; 97(6):1314-21. PubMed ID: 16686731 [TBL] [Abstract][Full Text] [Related]
8. Selective depletion of Foxp3+ regulatory T cells improves effective therapeutic vaccination against established melanoma. Klages K; Mayer CT; Lahl K; Loddenkemper C; Teng MW; Ngiow SF; Smyth MJ; Hamann A; Huehn J; Sparwasser T Cancer Res; 2010 Oct; 70(20):7788-99. PubMed ID: 20924102 [TBL] [Abstract][Full Text] [Related]
9. In vivo elimination of CD25+ regulatory T cells leads to tumor rejection of B16F10 melanoma, when combined with interleukin-12 gene transfer. Nagai H; Horikawa T; Hara I; Fukunaga A; Oniki S; Oka M; Nishigori C; Ichihashi M Exp Dermatol; 2004 Oct; 13(10):613-20. PubMed ID: 15447721 [TBL] [Abstract][Full Text] [Related]
10. Depletion of CD4+CD25+ regulatory T cells enhances interleukin-2-induced antitumor immunity in a mouse model of colon adenocarcinoma. Imai H; Saio M; Nonaka K; Suwa T; Umemura N; Ouyang GF; Nakagawa J; Tomita H; Osada S; Sugiyama Y; Adachi Y; Takami T Cancer Sci; 2007 Mar; 98(3):416-23. PubMed ID: 17270031 [TBL] [Abstract][Full Text] [Related]
11. Vaccination against the forkhead family transcription factor Foxp3 enhances tumor immunity. Nair S; Boczkowski D; Fassnacht M; Pisetsky D; Gilboa E Cancer Res; 2007 Jan; 67(1):371-80. PubMed ID: 17210720 [TBL] [Abstract][Full Text] [Related]
12. Regulatory T cells are necessary for implantation and maintenance of early pregnancy but not late pregnancy in allogeneic mice. Shima T; Sasaki Y; Itoh M; Nakashima A; Ishii N; Sugamura K; Saito S J Reprod Immunol; 2010 Jun; 85(2):121-9. PubMed ID: 20439117 [TBL] [Abstract][Full Text] [Related]
13. Downregulation of CD4+CD25+ regulatory T cells may underlie enhanced Th1 immunity caused by immunization with activated autologous T cells. Cao Q; Wang L; Du F; Sheng H; Zhang Y; Wu J; Shen B; Shen T; Zhang J; Li D; Li N Cell Res; 2007 Jul; 17(7):627-37. PubMed ID: 17563757 [TBL] [Abstract][Full Text] [Related]
14. Enhancement of anti-tumor immunity by high levels of Th1 and Th17 with a combination of dendritic cell fusion hybrids and regulatory T cell depletion in pancreatic cancer. Yamamoto M; Kamigaki T; Yamashita K; Hori Y; Hasegawa H; Kuroda D; Moriyama H; Nagata M; Ku Y; Kuroda Y Oncol Rep; 2009 Aug; 22(2):337-43. PubMed ID: 19578774 [TBL] [Abstract][Full Text] [Related]
15. Changes of CD4+CD25+Foxp3+ regulatory T cells in aged Balb/c mice. Zhao L; Sun L; Wang H; Ma H; Liu G; Zhao Y J Leukoc Biol; 2007 Jun; 81(6):1386-94. PubMed ID: 17369496 [TBL] [Abstract][Full Text] [Related]
16. Peripheral T-cell tolerance associated with prostate cancer is independent from CD4+CD25+ regulatory T cells. Degl'Innocenti E; Grioni M; Capuano G; Jachetti E; Freschi M; Bertilaccio MT; Hess-Michelini R; Doglioni C; Bellone M Cancer Res; 2008 Jan; 68(1):292-300. PubMed ID: 18172322 [TBL] [Abstract][Full Text] [Related]
17. Combinations of tumor-specific CD8+ CTLs and anti-CD25 mAb provide improved immunotherapy. Ohmura Y; Yoshikawa K; Saga S; Ueda R; Kazaoka Y; Yamada S Oncol Rep; 2008 May; 19(5):1265-70. PubMed ID: 18425386 [TBL] [Abstract][Full Text] [Related]
18. Interleukin-2 blocks the antitumour activity caused by depletion of CD25 cells in a murine renal adenocarcinoma model. Takeuchi T; Konno-Takahashi N; Kasuya Y; Ogushi T; Nishimatsu H; Kitamura T BJU Int; 2004 Jul; 94(1):171-6. PubMed ID: 15217455 [TBL] [Abstract][Full Text] [Related]
19. Targeting CD4+CD25+FoxP3+ regulatory T-cells for the augmentation of cancer immunotherapy. Schabowsky RH; Madireddi S; Sharma R; Yolcu ES; Shirwan H Curr Opin Investig Drugs; 2007 Dec; 8(12):1002-8. PubMed ID: 18058571 [TBL] [Abstract][Full Text] [Related]
20. Targeting acute allograft rejection by immunotherapy with ex vivo-expanded natural CD4+ CD25+ regulatory T cells. Xia G; He J; Zhang Z; Leventhal JR Transplantation; 2006 Dec; 82(12):1749-55. PubMed ID: 17198271 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]